Literature DB >> 9120003

Murine mucopolysaccharidosis type VII: long term therapeutic effects of enzyme replacement and enzyme replacement followed by bone marrow transplantation.

M S Sands1, C Vogler, A Torrey, B Levy, B Gwynn, J Grubb, W S Sly, E H Birkenmeier.   

Abstract

We demonstrated previously that short term administration of recombinant beta-glucuronidase to newborn mice with mucopolysaccharidosis type VII reduced lysosomal storage in many tissues. Lysosomal storage accumulated gradually after cessation of enzyme replacement therapy. Mice alive at 1 yr of age had decreased bone deformities and less lysosomal storage in cortical neurons. Here we compare the effects of long term enzyme replacement initiated either at birth or at 6 wk of age, and of enzyme administration initiated at birth followed by syngeneic bone marrow transplantation (BMT) at 5 wk of age. Several mice from each treatment group lived to at least 1 yr of age. Liver and spleen samples had beta-glucuronidase levels ranging from 2.4 to 19.8% of normal and showed a parallel decrease in lysosomal storage. The combination of enzyme replacement therapy followed by BMT reduced lysosomal distension in meninges, corneal fibroblasts, and bone when compared with treatment with enzyme alone. Mice treated at birth had less lysosomal storage in some neurons of the brain and the skeletal dysplasia was less severe when compared to mice whose treatment was delayed until 6 wk of age. We conclude that both enzyme replacement alone and early enzyme replacement followed by BMT have long term positive effects on murine mucopolysaccharidosis type VII. In addition, treatment started at birth is far more effective than treatment initiated in young adults.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9120003      PMCID: PMC507979          DOI: 10.1172/JCI119322

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  38 in total

1.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

2.  Beta glucuronidase deficiency: report of clinical, radiologic, and biochemical features of a new mucopolysaccharidosis.

Authors:  W S Sly; B A Quinton; W H McAlister; D L Rimoin
Journal:  J Pediatr       Date:  1973-02       Impact factor: 4.406

3.  Direct enzyme transfer from lymphocytes is specific.

Authors:  I Olsen; H Muir; R Smith; A Fensom; D J Watt
Journal:  Nature       Date:  1983 Nov 3-9       Impact factor: 49.962

4.  Identification and characterization of cells deficient in the mannose 6-phosphate receptor: evidence for an alternate pathway for lysosomal enzyme targeting.

Authors:  C A Gabel; D E Goldberg; S Kornfeld
Journal:  Proc Natl Acad Sci U S A       Date:  1983-02       Impact factor: 11.205

5.  Beta-glucuronidase binding to human fibroblast membrane receptors.

Authors:  H D Fischer; A Gonzalez-Noriega; W S Sly
Journal:  J Biol Chem       Date:  1980-06-10       Impact factor: 5.157

6.  Prolonged survival and remyelination after hematopoietic cell transplantation in the twitcher mouse.

Authors:  A M Yeager; S Brennan; C Tiffany; H W Moser; G W Santos
Journal:  Science       Date:  1984-09-07       Impact factor: 47.728

7.  A single-base-pair deletion in the beta-glucuronidase gene accounts for the phenotype of murine mucopolysaccharidosis type VII.

Authors:  M S Sands; E H Birkenmeier
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-15       Impact factor: 11.205

8.  Beta-glucuronidase deficiency in a dog: a model of human mucopolysaccharidosis VII.

Authors:  M E Haskins; R J Desnick; N DiFerrante; P F Jezyk; D F Patterson
Journal:  Pediatr Res       Date:  1984-10       Impact factor: 3.756

9.  Bone-marrow transplantation in the Maroteaux-Lamy syndrome (mucopolysaccharidosis type VI). Biochemical and clinical status 24 months after transplantation.

Authors:  W Krivit; M E Pierpont; K Ayaz; M Tsai; N K Ramsay; J H Kersey; S Weisdorf; R Sibley; D Snover; M M McGovern
Journal:  N Engl J Med       Date:  1984-12-20       Impact factor: 91.245

10.  Clearing of cornea after perforating keratoplasty in mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome)

Authors:  G Naumann
Journal:  N Engl J Med       Date:  1985-04-11       Impact factor: 91.245

View more
  32 in total

Review 1.  Brain-directed gene therapy for lysosomal storage disease: going well beyond the blood- brain barrier.

Authors:  William S Sly; Carole Vogler
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-30       Impact factor: 11.205

2.  Therapeutic efficacy of bone marrow transplant, intracranial AAV-mediated gene therapy, or both in the mouse model of MPS IIIB.

Authors:  Coy D Heldermon; Kevin K Ohlemiller; Erik D Herzog; Carole Vogler; Elizabeth Qin; David F Wozniak; Yun Tan; John L Orrock; Mark S Sands
Journal:  Mol Ther       Date:  2010-02-23       Impact factor: 11.454

3.  Bone marrow transplantation prolongs life span and ameliorates neurologic manifestations in Sandhoff disease mice.

Authors:  F Norflus; C J Tifft; M P McDonald; G Goldstein; J N Crawley; A Hoffmann; K Sandhoff; K Suzuki; R L Proia
Journal:  J Clin Invest       Date:  1998-05-01       Impact factor: 14.808

4.  Biochemical evidence for superior correction of neuronal storage by chemically modified enzyme in murine mucopolysaccharidosis VII.

Authors:  Ha T Huynh; Jeffrey H Grubb; Carole Vogler; William S Sly
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-01       Impact factor: 11.205

Review 5.  Murine mucopolysaccharidosis type VII: the impact of therapies on the clinical course and pathology in a murine model of lysosomal storage disease.

Authors:  C Vogler; M S Sands; N Galvin; B Levy; C Thorpe; J Barker; W S Sly
Journal:  J Inherit Metab Dis       Date:  1998-08       Impact factor: 4.982

Review 6.  Animal models of lysosomal disease: an overview.

Authors:  K Suzuki; J E Månsson
Journal:  J Inherit Metab Dis       Date:  1998-08       Impact factor: 4.982

7.  Glycosylation-independent targeting enhances enzyme delivery to lysosomes and decreases storage in mucopolysaccharidosis type VII mice.

Authors:  Jonathan H LeBowitz; Jeffrey H Grubb; John A Maga; Deborah H Schmiel; Carole Vogler; William S Sly
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-19       Impact factor: 11.205

8.  Developmentally regulated mannose 6-phosphate receptor-mediated transport of a lysosomal enzyme across the blood-brain barrier.

Authors:  Akihiko Urayama; Jeffrey H Grubb; William S Sly; William A Banks
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-16       Impact factor: 11.205

Review 9.  Combination Therapies for Lysosomal Storage Diseases: A Complex Answer to a Simple Problem.

Authors:  Shannon L Macauley
Journal:  Pediatr Endocrinol Rev       Date:  2016-06

10.  Correction of murine galactosialidosis by bone marrow-derived macrophages overexpressing human protective protein/cathepsin A under control of the colony-stimulating factor-1 receptor promoter.

Authors:  C N Hahn; M del Pilar Martin; X Y Zhou; L W Mann; A d'Azzo
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-08       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.